2015
DOI: 10.1016/j.clbc.2014.09.010
|View full text |Cite
|
Sign up to set email alerts
|

The Efficacy and Safety of Preoperative Chemotherapy With Triweekly Abraxane and Cyclophosphamide Followed by 5-Fluorouracil, Epirubicin, and Cyclophosphamide Therapy for Resectable Breast Cancer: A Multicenter Clinical Trial

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
12
0

Year Published

2015
2015
2024
2024

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 26 publications
(12 citation statements)
references
References 25 publications
0
12
0
Order By: Relevance
“…A phase II trial of nab -paclitaxel 260 mg/m 2  q3w and cyclophosphamide 600 mg/m 2 followed by fluorouracil, epirubicin, and cyclophosphamide (FEC) q3w for operable breast cancer resulted in a pCR rate of 37% (95% CI 24–50%) [10]. Hormone receptor–positive/HER2-negative tumors demonstrated the lowest pCR rate (8%), whereas all other molecular subgroups had pCR rates ranging from 56 to 63%.…”
Section: Resultsmentioning
confidence: 99%
“…A phase II trial of nab -paclitaxel 260 mg/m 2  q3w and cyclophosphamide 600 mg/m 2 followed by fluorouracil, epirubicin, and cyclophosphamide (FEC) q3w for operable breast cancer resulted in a pCR rate of 37% (95% CI 24–50%) [10]. Hormone receptor–positive/HER2-negative tumors demonstrated the lowest pCR rate (8%), whereas all other molecular subgroups had pCR rates ranging from 56 to 63%.…”
Section: Resultsmentioning
confidence: 99%
“…Although Nab-PTX has been widely used for metastatic breast cancer (7,14,15), there are only a few reports on the therapeutic efficacy and safety profile of Nab-PTX monotherapy in an upfront setting (16)(17)(18). Moreover, most studies of neoadjuvant Nab-PTX in breast cancer reported on the every-3-week (q3w) Nab-PTX administration regimen (16,17,(19)(20)(21) (22).…”
Section: Discussionmentioning
confidence: 99%
“…Moreover, most studies of neoadjuvant Nab-PTX in breast cancer reported on the every-3-week (q3w) Nab-PTX administration regimen (16,17,(19)(20)(21) (22). Chemotherapy agents, including taxanes, which are recommended in the metastatic (23) and adjuvant settings (24), are also considered in the neoadjuvant setting.…”
Section: Discussionmentioning
confidence: 99%
“…Third, adoption of concurrent regimens with other agents could be preferred over nab-PTX monotherapy. Some investigations have displayed a favorable pCR rate of 20-50% in HER2-negative patients who received qw nab-PTX in combination with carboplatin and bevacizumab in a neoadjuvant setting (17,23,24). Thus, the majority of neoadjuvant studies with nab-PTX have demonstrated satisfactory efficacy in combination regimes, but have not compared it with solvent-based taxanes (19).…”
Section: Discussionmentioning
confidence: 99%